You Searched For "ADUHELM" and got 20 results
Sort By:
3 mins read
Medicare sticks by decision to limit coverage of a controversial Alzheimer's drug to people involved in clinical trials
The Medicare coverage decision is a blow for Biogen, which has struggled with sales of its new drug…
Allison DeAngelis
2 mins read
Read the FDA report on the death of a woman who was taking a new Alzheimer's drug, reigniting safety concerns
These are Insider's biggest healthcare stories for December 13.
Leah Rosenbaum
2 mins read
The head of the FDA is calling for an investigation into her agency's controversial decision to approve a new Alzheimer's drug
The decision to approve Aduhelm has raised concerns and led three advisors to resign. The agency's …
Allison DeAngelis
3 mins read
Hot upstart insurer Bright Health stumbles in its stock-market debut
These are Insider's biggest healthcare stories for the week ending June 25.
Shelby Livingston
2 mins read
The FDA approved a controversial, $56,000-a-year Alzheimer's drug despite opposition inside the agency, internal memos show
The director of the FDA's biostatistics office said there wasn't enough evidence to approve Aduhelm…
Allison DeAngelis
2 mins read
Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm
Medicare seeks to only cover patients who are enrolled in clinical trials evaluating Aduhelm, a dru…
Carla Mozée
3 mins read
Alzheimer's nasal vaccine to enter human trials for the first time, spurring renewed hope for preventing the disease
Brigham and Women's Hospital is conducting the first human trial of an Alzheimer's nasal vaccine me…
Aria Bendix
2 mins read
Biogen falls 8% after 2 major hospital systems say they won't administer controversial Alzheimer's drug
The next big hurdle for Biogen will be receiving approval from health insurers to cover the costs o…
Matthew Fox
3 mins read
An experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
In a late-stage trial, Eli Lilly's experimental Alzheimer's treatment slowed the rate of cognitive …
Yeji Jesse Lee
2 mins read
A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug
Dr. Aaron Kesselheim said the agency's decision to approve Biogen's new drug "was probably the wors…
Erin Snodgrass
3 mins read
The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease
Two Alzheimer's drugs, Biogen's Leqembi and Eli Lilly's donanemab, treat the disease by focusing on…
Yeji Jesse Lee
4 mins read
The FDA just approved a new Alzheimer's drug that's set to be a blockbuster
The new drug, called Leqembi, slowed the rate of cognitive decline in Alzheimer's patients by 27%.
Yeji Jesse Lee
4 mins read
We read through the 45-page congressional investigation into Biogen's Alzheimer's drug. Here are the 3 most shocking takeaways.
The investigation found that Biogen knew the drug's hefty price tag would make the medication inacc…
Yeji Jesse Lee,Leah Rosenbaum
4 mins read
This Alzheimer’s drug slowed cognitive decline in some patients. Analysts say it could become a blockbuster hit.
Full results of Biogen and Eisai's Alzheimer's study on lecanemab give some credence to a controver…
Yeji Jesse Lee
2 mins read
Why 2022 could be the most crucial year yet for gene editing
These are Insider's biggest healthcare stories for December 21.
Lydia Ramsey Pflanzer,Leah Ro…
2 mins read
Biotech's top investors, ranked
These are Insider's biggest healthcare stories for December 9.
Leah Rosenbaum
2 mins read
We got our best picture yet of Dollar General's healthcare plans
These are Insider's biggest healthcare stories for August 30.
Lydia Ramsey Pflanzer
2 mins read
The 9 behind-the-scenes professionals you need to know in digital health
These are Insider's biggest healthcare stories for July 28.
Lydia Ramsey Pflanzer
1 min read
Vaccinated people: Don't panic about your odds of a 'breakthrough' infection
These are Insider's biggest healthcare stories for July 21.
Lydia Ramsey Pflanzer
2 mins read
Moderna confronts a $100 billion question
These are Insider's biggest healthcare stories for July 12.